Found: 41
Select item for more details and to access through your institution.
Update on Malignant Mesothelioma.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 10, p. 1301
- By:
- Publication type:
- Article
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
- Published in:
- Journal of Patient-Reported Outcomes, 2019, v. 3, n. 1, p. N.PAG, doi. 10.1186/s41687-019-0122-5
- By:
- Publication type:
- Article
Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 8, p. 838, doi. 10.1001/jamadermatol.2024.1804
- By:
- Publication type:
- Article
NAV‐003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors.
- Published in:
- European Journal of Immunology, 2023, v. 53, n. 8, p. 1, doi. 10.1002/eji.202250309
- By:
- Publication type:
- Article
CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
- Published in:
- Journal of Pathology, 2020, v. 250, n. 2, p. 205, doi. 10.1002/path.5361
- By:
- Publication type:
- Article
Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.
- Published in:
- American Journal of Industrial Medicine, 2020, v. 63, n. 2, p. 105, doi. 10.1002/ajim.23062
- By:
- Publication type:
- Article
111INDIUM-LABELED MONOCLONAL ANTIBODY K1: BIODISTRIBUTION STUDY IN NUDE MICE BEARING A HUMAN CARCINOMA XENOGRAFT EXPRESSING MESOTHELIN.
- Published in:
- International Journal of Cancer, 1999, v. 80, n. 4, p. 559, doi. 10.1002/(SICI)1097-0215(19990209)80:4<559::AID-IJC13>3.0.CO;2-Y
- By:
- Publication type:
- Article
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2012, v. 50, n. 4, p. 721, doi. 10.1515/cclm.2011.816
- By:
- Publication type:
- Article
A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2013, v. 20, n. 2, p. 555, doi. 10.1245/s10434-012-2651-5
- By:
- Publication type:
- Article
Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice.
- Published in:
- PLoS ONE, 2014, v. 9, n. 8, p. 1, doi. 10.1371/journal.pone.0104388
- By:
- Publication type:
- Article
DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma.
- Published in:
- PLoS ONE, 2012, v. 7, n. 2, p. 1, doi. 10.1371/journal.pone.0031507
- By:
- Publication type:
- Article
The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy.
- Published in:
- PLoS ONE, 2011, v. 6, n. 1, p. 1, doi. 10.1371/journal.pone.0014640
- By:
- Publication type:
- Article
Clinical and Pathological Features Are Still the Best Determinants of Prognosis in Mesothelioma.
- Published in:
- Oncology (08909091), 2012, v. 26, n. 12, p. 1176
- By:
- Publication type:
- Article
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 5, p. 737, doi. 10.1007/s00262-009-0794-4
- By:
- Publication type:
- Article
Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.
- Published in:
- Journal of Applied Laboratory Medicine, 2018, p. 166, doi. 10.1373/jalm.2017.025015
- By:
- Publication type:
- Article
Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 4236, doi. 10.1002/cam4.5290
- By:
- Publication type:
- Article
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
- Published in:
- European Journal of Haematology, 2007, v. 79, n. 4, p. 281, doi. 10.1111/j.1600-0609.2007.00928.x
- By:
- Publication type:
- Article
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 550, p. 1, doi. 10.1126/scitranslmed.aaz7252
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
18F-FDG-PET assessment of malignant pleural mesothelioma: Total lesion volume and Total lesion glycolysis; the central role of volume.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.238733
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
- Published in:
- International Journal of Cancer, 2012, v. 131, n. 9, p. 2143, doi. 10.1002/ijc.27471
- By:
- Publication type:
- Article
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 208, p. 1, doi. 10.1126/scitranslmed.3006941
- By:
- Publication type:
- Article
CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma.
- Published in:
- Journal of Pathology: Clinical Research, 2023, v. 9, n. 3, p. 195, doi. 10.1002/cjp2.310
- By:
- Publication type:
- Article
New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma.
- Published in:
- Scientific Reports, 2015, p. 9928, doi. 10.1038/srep09928
- By:
- Publication type:
- Article
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 21, p. 3311, doi. 10.1002/cncr.28875
- By:
- Publication type:
- Article
Advances in Anticancer Immunotoxin Therapy.
- Published in:
- Oncologist, 2015, v. 20, n. 2, p. 176, doi. 10.1634/theoncologist.2014-0358
- By:
- Publication type:
- Article
Malignant Mesothelioma and Central Nervous System Metastases.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 7, p. 1010, doi. 10.1002/cncr.33433
- By:
- Publication type:
- Article
Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4936, doi. 10.1002/cncr.33145
- By:
- Publication type:
- Article
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
- Published in:
- BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1362-2
- By:
- Publication type:
- Article
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Immunotoxin therapy of cancer.
- Published in:
- 2006
- By:
- Publication type:
- research
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00343
- By:
- Publication type:
- Article
Pretargeted Radioimmunotherapy of Mesothelin- Expressing Cancer Using a Tetravalent Single- Chain Fv-Streptavidin Fusion Protein.
- Published in:
- Journal of Nuclear Medicine, 2005, v. 46, n. 7, p. 1201
- By:
- Publication type:
- Article